Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges

João Faro-Viana, Marie-Louise Bergman, Lígia A. Gonçalves, Nádia Duarte, Teresa P. Coutinho, Patrícia C. Borges, Christian Diwo, Rute Castro, Paula Matoso, Vanessa Malheiro, Ana Brennand, Lindsay Kosack, Onome Akpogheneta, João M. Figueira, Conceição Cardoso, Ana M. Casaca, Paula M. Alves, Telmo Nunes, Carlos Penha-Gonçalves () and Jocelyne Demengeot ()
Additional contact information
João Faro-Viana: CHLO, Centro Hospitalar de Lisboa Ocidental, Serviço de Patologia Clínica
Marie-Louise Bergman: IGC, Instituto Gulbenkian de Ciência
Lígia A. Gonçalves: IGC, Instituto Gulbenkian de Ciência
Nádia Duarte: IGC, Instituto Gulbenkian de Ciência
Teresa P. Coutinho: University of Lisbon
Patrícia C. Borges: IGC, Instituto Gulbenkian de Ciência
Christian Diwo: IGC, Instituto Gulbenkian de Ciência
Rute Castro: IBET, Instituto de Biologia Experimental e Tecnológica
Paula Matoso: IGC, Instituto Gulbenkian de Ciência
Vanessa Malheiro: IGC, Instituto Gulbenkian de Ciência
Ana Brennand: IGC, Instituto Gulbenkian de Ciência
Lindsay Kosack: IGC, Instituto Gulbenkian de Ciência
Onome Akpogheneta: IGC, Instituto Gulbenkian de Ciência
João M. Figueira: CHLO, Centro Hospitalar de Lisboa Ocidental, Serviço de Patologia Clínica
Conceição Cardoso: CHLO, Centro Hospitalar de Lisboa Ocidental, Serviço de Patologia Clínica
Ana M. Casaca: CHLO, Centro Hospitalar de Lisboa Ocidental, Serviço de Patologia Clínica
Paula M. Alves: IBET, Instituto de Biologia Experimental e Tecnológica
Telmo Nunes: University of Lisbon
Carlos Penha-Gonçalves: IGC, Instituto Gulbenkian de Ciência
Jocelyne Demengeot: IGC, Instituto Gulbenkian de Ciência

Nature Communications, 2022, vol. 13, issue 1, 1-8

Abstract: Abstract While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-27761-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-021-27761-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-27761-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().